**Pharmaceutical companies reportedly pressured Biden administration to reverse loosening of rules for generic drugs**
A report by the Wall Street Journal on Thursday said pharmaceutical giants have been lobbying the Biden administration to reverse a Trump-era loosening of rules that allowed more generic drugs to reach the market and save consumers money.
Generic drug manufacturers have long argued that the Food and Drug Administration (FDA) has made it too difficult for them to produce and sell cheaper versions of brand-name drugs, which has led to higher prices for consumers.
In 2019, the Trump administration finalized a rule that made it easier for generic drug manufacturers to get their products approved by the FDA. The rule, known as the .
